

NPCA, Clinical Effectiveness Unit Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: NPCA@rcseng.ac.uk


T: 020 7869 6602 in LinkedIn


NPCA Newsletter, November 2025

State of the Nation Report 2025

The NPCA State of the Nation Report 2025 was published on Thursday 9th October 2025. More information is available on our new website.

The report includes results for eight performance indicators for people diagnosed or treated with prostate cancer from 1 September 2021 to 31 March 2024 in England and Wales, and a description of national time trends in diagnoses and treatments from 1 January 2019 to 31 December 2024 in England and 1 January 2022 to 31 December 2023 in Wales.





This year, results for individual providers are available on our data dashboard.

For the first time, we report the **proportion of men with metastatic disease who receive systemic treatment intensification** (PI4a and PI4b) and report the **proportion of men experiencing at least one genitourinary (GU) complication** following **radical prostate radiotherapy** (PI8).

Left: adjusted funnel plot for the proportion of men aged 75 years and above with mHSPC who received treatment intensification therapy between 1st January 2022 and 31st December 2022 in England by sMDT.

Parliamentary Reception

The team co-hosted the launch of the NPCA State of the Nation Report alongside **Prostate Cancer UK** and **Danny Beales MP** on **13th October 2025** at the Houses of Parliament. NPCA Clinical Lead,



Professor Noel Clarke, joined the expert panel to share insights into the significant variations in prostate cancer treatment across England and Wales.

The event **highlighted the inequalities** affecting Black men and those in deprived areas, and reinforced the call for equitable, high-quality care for all men.

Quality Improvement Intervention

The NPCA has launched its quality improvement initiative to ensure men with hormone-sensitive metastatic prostate cancer receive treatment intensification therapy where appropriate.

In collaboration with BURST, we hosted a <u>webinar</u> on 23rd October exploring the use of anti-cancer systemic therapy in metastatic prostate cancer.

New team member

Justin Liu, Clinical Fellow, joined the NPCA team on 3rd September.



Previously, he was a Higher Specialist Clinical Trainee in Medical Oncology at Yorkshire and the Humber Deanery. Welcome!

State of the Nation Webinar

NATCAN hosted a webinar to discuss **key findings** from the State of the Nation Reports from nine audits on 13th October.

NPCA Clinical Fellow, **Arjun Nathan**, presented NPCA's
results and shared valuable
insights. **Watch the full session**on the NATCAN website.

